Blood-Based Liquid Biopsy Test for Lung and Colon Cancer Patients
Studies a blood-based cancer test in adults with lung or colon cancer.
Plain-language title generated from the registry record
Registry title: Liquid BiOpsy, Lung and Colon Cancer in AndaluciA
Key facts
- Where
- Granada, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV lung adenocarcinoma (a type of non-small cell lung cancer) or stage IV colorectal adenocarcinoma who have not had any treatment yet.
- Age
- More than 18 years old
- Sex
- Men and women can join
- Disease stage
- Stage IV (Any T, Any N, M1a-c). Lung cancer: confirmed non-small cell lung cancer (adenocarcinoma). Colorectal cancer: confirmed adenocarcinoma. ECOG performance status 0-2. Expected life of 3 months or more.
- Earlier treatment
- No earlier chemotherapy, immunotherapy, targeted therapy or radiotherapy.
Main reasons for not taking part
- Another cancer in the previous 5 years, except non-melanoma skin cancer
- Small cell lung cancer
- Pregnant or nursing women
- Not able to give written informed consent
Read by machine on 12 November 2026.
Where in Spain
- Centre for Genomics and Oncological Research - Pfizer - University of Granada - Andalusian Regional Government (GENyO)Granada, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
- Trial code
- NCT06997458
- Record updated
- 30 May 2025
- Original description
The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of clinical impact, duration of turnaround time (TAT) of xF test vs standard of care and the analysis of resource utilisation.Read full original descriptionShow less
Clinical Implementation of Liquid Biopsy in Cancer Through Next Generation Sequencing (NGS) Panels in the Andalusian Public Health System
The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of clinical impact, duration of turnaround time (TAT) of xF test vs standard of care and the analysis of resource utilisation.
Inclusion: General criteria:; More than 18 years old; Both genders; Ability to provide written informed consent; Specific criteria:; NSCLC; Patients diagnosed with the 8th Edition of the Tumor, Node, Metastasis (TNM) staging system for Lung Cancer approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c); Histologically confirmed NSCLC (adenocarcinoma); Performance status of 0-2 (ECOG PS) ○ Estimated life expectancy ≥3 months; Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy); Smokers or Non-Smokers; CRC; Patients diagnosed with the Tumor, Node, Metastasis (TNM) staging system for Colorectal Cancer approved by the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c); Histologically confirmed CRC (adenocarcinoma); Performance status of 0-2 (ECOG PS); Estimated life expectancy ≥3 months; Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).
Exclusion: General: History of any other cancer within the previous 5 years, except non-melanoma skin cancer; General: Absence of Informed consent. > Pregnant or nursing women. > Small cell lung cancer.